Regeneron Pharmaceuticals, Inc.
Huda Y Zoghbi (Director) sells REGN shares
AI-generated summary
Director Huda Y Zoghbi exercised options for 7,439 shares of Common Stock at an average price of $380.95 worth $2,833,887.05. Huda Y Zoghbi also sold 7,439 shares of Common Stock in an open-market sale at an average price of $970.46 worth $7,219,274.38. Huda Y Zoghbi directly holds 1,703 shares of Common Stock afterwards.
Key facts
- Insider
- Huda Y Zoghbi · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | M · exercise or conversion of a derivative | +7,439 | $380.95 | $2,833,887.05 | 9,142 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F1 | −6,939 | $970.42 | $6,733,744.38 | 2,203 | Direct |
| Nov 3, 2026 | S · open-market saleFootnotes F2 | −500 | $971.06 | $485,530.00 | 1,703 | Direct |
| Nov 3, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F3 | −7,439 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 Represents volume-weighted average price of sales of 6,939 shares of Company stock on November 3, 2026 at prices ranging from $970.00 to $970.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price.
- F2 Represents volume-weighted average price of sales of 500 shares of Company stock on November 3, 2026 at prices ranging from $971.00 to $971.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price.
- F3 The stock option vested in three equal annual installments, commencing one year after the date of grant.
More REGN filings
- 4
Filed Nov 5, 2026
- 13F-HR
Filed Nov 5, 2026
- 144
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.